Plumericin’s capacity to modulate both AhR and NF-κB pathways highlights the potential crosstalk between these routes in CKD-related complications, suggesting that plumericin may interfere with IS-induced signaling at multiple points. This evidence concerns the gene NFKB1 and chronic kidney disease.